BG-75202 features among several projects starting first-in-human trials.
ApexOnco Front Page
Recent articles
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.
Genmab quietly reveals pipeline discontinuations and a delay to the son of Darzalex.
Kura will see more combo data, while a new contender from Sumitomo emerges.
Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.
Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.
The company abandons TNG908, but is still all in on the troubled target.
